首页 > 最新文献

Canadian Journal of Gastroenterology and Hepatology最新文献

英文 中文
Wulingsan Alleviates MAFLD by Activating Autophagy via Regulating the AMPK/mTOR/ULK1 Signaling Pathway. 五灵脂通过调节AMPK/mTOR/ULK1信号通路激活自噬作用缓解MAFLD
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-07-13 eCollection Date: 2024-01-01 DOI: 10.1155/2024/9777866
Yaning Biao, Dantong Li, Yixin Zhang, Jingmiao Gao, Yi Xiao, Zehe Yu, Li Li

Here, we presented the study of the molecular mechanisms underlying the action of Wulingsan (WLS) in rats with metabolic-associated fatty liver disease (MAFLD) induced by a high-fat diet (HFD). High-performance liquid chromatography was employed to identify the chemical components of WLS. After 2 weeks of HFD induction, MAFLD rats were treated with WLS in three different doses for 6 weeks, a positive control treatment or with a vehicle. Lipid metabolism, liver function, oxidative stress, and inflammatory factors as well as pathomorphological changes in liver parenchyma were assessed in all groups. Finally, the expressions of autophagy-related markers, adenosine monophosphate-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR)/unc-51-like kinase-1 (ULK1) signaling pathway-related genes, and proteins in liver were detected. The results revealed that WLS significantly ameliorated liver injury, the dysfunction of the lipid metabolism, the oxidative stress, and overall inflammatory status. Furthermore, WLS increased the expressions of LC3B-II, Beclin1, p-AMPK, and ULK1, along with decreased p62, p-mTOR, and sterol regulatory element-binding protein-1c levels. In conclusion, we showed that WLS is capable of alleviating HFD-induced MAFLD by improving lipid accumulation, suppressing oxidative stress and inflammation, and promoting autophagy.

在此,我们介绍了五灵散(WLS)对高脂饮食(HFD)诱导的代谢相关性脂肪肝(MAFLD)大鼠作用的分子机制研究。采用高效液相色谱法鉴定五灵散的化学成分。高脂饮食诱导 MAFLD 大鼠 2 周后,分别用三种不同剂量的 WLS、阳性对照组或药物治疗 MAFLD 大鼠 6 周。对所有组的脂质代谢、肝功能、氧化应激和炎症因子以及肝实质的病理形态学变化进行了评估。最后,检测了自噬相关标志物、单磷酸腺苷激活蛋白激酶(AMPK)/雷帕霉素机械靶标(mTOR)/unc-51样激酶-1(ULK1)信号通路相关基因和蛋白质在肝脏中的表达。结果显示,WLS能明显改善肝损伤、脂质代谢障碍、氧化应激和整体炎症状态。此外,WLS还增加了LC3B-II、Beclin1、p-AMPK和ULK1的表达,降低了p62、p-mTOR和固醇调节元件结合蛋白-1c的水平。总之,我们的研究表明,WLS 能够通过改善脂质积累、抑制氧化应激和炎症反应以及促进自噬来缓解 HFD 诱导的 MAFLD。
{"title":"Wulingsan Alleviates MAFLD by Activating Autophagy via Regulating the AMPK/mTOR/ULK1 Signaling Pathway.","authors":"Yaning Biao, Dantong Li, Yixin Zhang, Jingmiao Gao, Yi Xiao, Zehe Yu, Li Li","doi":"10.1155/2024/9777866","DOIUrl":"10.1155/2024/9777866","url":null,"abstract":"<p><p>Here, we presented the study of the molecular mechanisms underlying the action of Wulingsan (WLS) in rats with metabolic-associated fatty liver disease (MAFLD) induced by a high-fat diet (HFD). High-performance liquid chromatography was employed to identify the chemical components of WLS. After 2 weeks of HFD induction, MAFLD rats were treated with WLS in three different doses for 6 weeks, a positive control treatment or with a vehicle. Lipid metabolism, liver function, oxidative stress, and inflammatory factors as well as pathomorphological changes in liver parenchyma were assessed in all groups. Finally, the expressions of autophagy-related markers, adenosine monophosphate-activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR)/unc-51-like kinase-1 (ULK1) signaling pathway-related genes, and proteins in liver were detected. The results revealed that WLS significantly ameliorated liver injury, the dysfunction of the lipid metabolism, the oxidative stress, and overall inflammatory status. Furthermore, WLS increased the expressions of LC3B-II, Beclin1, p-AMPK, and ULK1, along with decreased p62, p-mTOR, and sterol regulatory element-binding protein-1c levels. In conclusion, we showed that WLS is capable of alleviating HFD-induced MAFLD by improving lipid accumulation, suppressing oxidative stress and inflammation, and promoting autophagy.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"2024 ","pages":"9777866"},"PeriodicalIF":2.7,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11260214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lobe-Based Hepatic Uptake Index of Gd-EOB-DTPA on Contrast-Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B-Related Cirrhosis. 对比增强磁共振成像中基于肝叶的 Gd-EOB-DTPA 肝摄取指数定量区分乙肝相关肝硬化的代偿期和失代偿期
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-06-21 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6623848
Fulin Lu, Bangguo Tan, Yucheng Huang, Lin Xu, Changqiang Wu, Haiying Zhou, Rui Li, Xiaoming Zhang, Tianwu Chen, Hongjun Li

Purpose: To use hepatic uptake index (HUI) of liver lobes on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) to discriminate between patients with hepatitis B-related cirrhosis in compensated and decompensated statuses.

Methods: Forty-four consecutive patients with hepatitis B-related cirrhosis who underwent Gd-EOB-DTPA-enhanced MRI were divided into compensated and decompensated statuses based on clinical evaluation. Volume and signal intensity of individual lobes were retrospectively measured to calculate HUI of the right liver lobe (RHUI), medial (MHUI) and lateral (LHUI) left liver lobes, and caudate lobe (CHUI). Spearman's rank correlation analyses were performed to evaluate relationships of lobe-based HUI with Child-Pugh and model for end-stage liver disease (MELD) scoring system scores in compensated and decompensated statuses. The Mann-Whitney U-test was used to compare the lobe-based HUI between compensated and decompensated statuses. The performance of lobe-based HUI in distinguishing cirrhosis was evaluated using receiver operating characteristic (ROC) analysis, and the area under the ROC curve (AUC) was calculated as a measure of accuracy. Delong's method was used for statistical analysis to elucidate which HUI is optimal.

Results: Compensated and decompensated liver cirrhosis were confirmed in 25 (56.82%) and 19 (43.18%) patients, respectively. According to Spearman's rank correlation analysis, RHUI, MHUI, LHUI, and CHUI were all significantly associated with Child-Pugh and MELD scores (all P values <0.05). Receiver operating characteristic analysis demonstrated that among all lobe-based HUI parameters, RHUI could best perform the previous discrimination with a cut-off of 485.73 and obtain an AUC of 0.867. The AUC of RHUI improved and was significantly different from that of MHUI, LHUI, and CHUI (P = 0.03, P = 0.007, and P < 0.001, respectively, Delong's test).

Conclusions: The RHUI could help quantitatively discriminate hepatitis B-related cirrhosis between compensated and decompensated statuses.

目的:利用钆乙氧苄基二乙三胺五乙酸(Gd-EOB-DTPA)增强磁共振成像(MRI)上的肝叶摄取指数(HUI)来区分乙肝相关肝硬化患者的代偿期和失代偿期:根据临床评估结果,将连续接受 Gd-EOB-DTPA 增强 MRI 检查的 44 例乙肝相关肝硬化患者分为代偿期和失代偿期。通过回顾性测量单个肝叶的体积和信号强度,计算右肝叶(RHUI)、左肝叶内侧(MHUI)和外侧(LHUI)以及尾状叶(CHUI)的 HUI。进行斯皮尔曼等级相关分析,以评估在代偿和失代偿状态下,基于肝叶的 HUI 与 Child-Pugh 和终末期肝病模型(MELD)评分系统评分的关系。曼-惠特尼 U 检验用于比较代偿期和失代偿期的肝叶 HUI。使用接收器操作特征(ROC)分析评估了基于肝叶的 HUI 在区分肝硬化方面的性能,并计算了 ROC 曲线下面积(AUC)作为准确性的衡量标准。德隆法用于统计分析,以阐明哪种 HUI 最佳:分别有 25 例(56.82%)和 19 例(43.18%)患者确诊为肝硬化代偿期和失代偿期。根据斯皮尔曼秩相关分析,RHUI、MHUI、LHUI 和 CHUI 均与 Child-Pugh 和 MELD 评分显著相关(所有 P 值分别为 P = 0.03、P = 0.007 和 P < 0.001,德隆检验):RHUI有助于定量区分乙肝相关肝硬化的代偿期和失代偿期。
{"title":"Lobe-Based Hepatic Uptake Index of Gd-EOB-DTPA on Contrast-Enhanced MRI to Quantitatively Discriminate between Compensated and Decompensated Hepatitis B-Related Cirrhosis.","authors":"Fulin Lu, Bangguo Tan, Yucheng Huang, Lin Xu, Changqiang Wu, Haiying Zhou, Rui Li, Xiaoming Zhang, Tianwu Chen, Hongjun Li","doi":"10.1155/2024/6623848","DOIUrl":"10.1155/2024/6623848","url":null,"abstract":"<p><strong>Purpose: </strong>To use hepatic uptake index (HUI) of liver lobes on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) to discriminate between patients with hepatitis B-related cirrhosis in compensated and decompensated statuses.</p><p><strong>Methods: </strong>Forty-four consecutive patients with hepatitis B-related cirrhosis who underwent Gd-EOB-DTPA-enhanced MRI were divided into compensated and decompensated statuses based on clinical evaluation. Volume and signal intensity of individual lobes were retrospectively measured to calculate HUI of the right liver lobe (RHUI), medial (MHUI) and lateral (LHUI) left liver lobes, and caudate lobe (CHUI). Spearman's rank correlation analyses were performed to evaluate relationships of lobe-based HUI with Child-Pugh and model for end-stage liver disease (MELD) scoring system scores in compensated and decompensated statuses. The Mann-Whitney U-test was used to compare the lobe-based HUI between compensated and decompensated statuses. The performance of lobe-based HUI in distinguishing cirrhosis was evaluated using receiver operating characteristic (ROC) analysis, and the area under the ROC curve (AUC) was calculated as a measure of accuracy. Delong's method was used for statistical analysis to elucidate which HUI is optimal.</p><p><strong>Results: </strong>Compensated and decompensated liver cirrhosis were confirmed in 25 (56.82%) and 19 (43.18%) patients, respectively. According to Spearman's rank correlation analysis, RHUI, MHUI, LHUI, and CHUI were all significantly associated with Child-Pugh and MELD scores (all <i>P</i> values <0.05). Receiver operating characteristic analysis demonstrated that among all lobe-based HUI parameters, RHUI could best perform the previous discrimination with a cut-off of 485.73 and obtain an AUC of 0.867. The AUC of RHUI improved and was significantly different from that of MHUI, LHUI, and CHUI (<i>P</i> = 0.03, <i>P</i> = 0.007, and <i>P</i> < 0.001, respectively, Delong's test).</p><p><strong>Conclusions: </strong>The RHUI could help quantitatively discriminate hepatitis B-related cirrhosis between compensated and decompensated statuses.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"2024 ","pages":"6623848"},"PeriodicalIF":2.7,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Outcomes of Ileostomy Closure during versus after Adjuvant Chemotherapy in Patients with Rectal Cancer 直肠癌患者在辅助化疗期间与化疗后关闭回肠造口的临床疗效对比
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-03-20 DOI: 10.1155/2024/2410643
Fan He, Fuyu Yang, Chenglin Tang, Defei Chen, Dongqin Zhao, Junjie Xiong, Yu Zou, Guoquan Huang, Kun Qian
Background. Protective ileostomy can effectively prevent severe anastomotic leakage after rectal cancer surgery; however, the optimal timing for ileostomy closure during adjuvant chemotherapy remains unclear. This study aimed to explore the safety and long-term outcomes of early ileostomy closure during adjuvant chemotherapy. Method. Patients who underwent laparoscopic rectal cancer surgery combined with protective ileostomy and adjuvant chemotherapy between April 2017 and April 2021 were retrospectively evaluated. Patients were divided into an early closure group during chemotherapy (group A) and a late closure group after chemotherapy (group B). Results. A total of 215 patients were included in this study, with 115 in group A and 100 in group B. There were no significant differences in demographic and clinical characteristics between the two groups. In group A, durations of stoma status () and low anterior resection syndrome (LARS) () were shorte
背景。保护性回肠造口能有效防止直肠癌术后严重吻合口漏;然而,辅助化疗期间回肠造口关闭的最佳时机仍不明确。本研究旨在探讨辅助化疗期间尽早关闭回肠造口的安全性和长期疗效。方法。对2017年4月至2021年4月期间接受腹腔镜直肠癌手术联合保护性回肠造口术和辅助化疗的患者进行回顾性评估。患者被分为化疗期间早期闭合组(A组)和化疗后晚期闭合组(B组)。结果两组患者的人口统计学和临床特征无显著差异。在 A 组中,造口状态()和低位前切除综合征()的持续时间较短,直肠狭窄()和造口相关并发症(),尤其是造口狭窄()较少见。然而,化疗的依从性较差()。各组之间在手术时间、术后住院时间、术后并发症、LARS 的发生率和严重程度、无病生存率和总生存率方面没有明显差异。结论早期关闭回肠造口可有效缩短造口状态持续时间、LARS持续时间、直肠狭窄和造口相关并发症,同时不会影响手术并发症和肿瘤预后。不应因辅助化疗而推迟回肠造口关闭时间。但应加强随访,以提高化疗的依从性和完整性。
{"title":"Clinical Outcomes of Ileostomy Closure during versus after Adjuvant Chemotherapy in Patients with Rectal Cancer","authors":"Fan He, Fuyu Yang, Chenglin Tang, Defei Chen, Dongqin Zhao, Junjie Xiong, Yu Zou, Guoquan Huang, Kun Qian","doi":"10.1155/2024/2410643","DOIUrl":"https://doi.org/10.1155/2024/2410643","url":null,"abstract":"<i>Background</i>. Protective ileostomy can effectively prevent severe anastomotic leakage after rectal cancer surgery; however, the optimal timing for ileostomy closure during adjuvant chemotherapy remains unclear. This study aimed to explore the safety and long-term outcomes of early ileostomy closure during adjuvant chemotherapy. <i>Method</i>. Patients who underwent laparoscopic rectal cancer surgery combined with protective ileostomy and adjuvant chemotherapy between April 2017 and April 2021 were retrospectively evaluated. Patients were divided into an early closure group during chemotherapy (group A) and a late closure group after chemotherapy (group B). <i>Results</i>. A total of 215 patients were included in this study, with 115 in group A and 100 in group B. There were no significant differences in demographic and clinical characteristics between the two groups. In group A, durations of stoma status (<span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.34882 18.973 11.7782\" width=\"18.973pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,11.342,0)\"></path></g></svg><span></span><span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"22.555183800000002 -8.34882 28.184 11.7782\" width=\"28.184pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.605,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,28.845,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,31.809,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.049,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.289,0)\"></path></g></svg>)</span></span> and low anterior resection syndrome (LARS) (<span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.34882 18.973 11.7782\" width=\"18.973pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"><use xlink:href=\"#g113-113\"></use></g><g transform=\"matrix(.013,0,0,-0.013,11.342,0)\"><use xlink:href=\"#g117-91\"></use></g></svg><span></span><span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"22.555183800000002 -8.34882 28.184 11.7782\" width=\"28.184pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.605,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,28.845,0)\"><use xlink:href=\"#g113-47\"></use></g><g transform=\"matrix(.013,0,0,-0.013,31.809,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.049,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.289,0)\"><use xlink:href=\"#g113-50\"></use></g></svg>)</span></span> were shorte","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"50 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140168230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study 炎症生物标志物在调解炎症性肠病对非恶性消化系统疾病影响中的作用:多变量孟德尔随机研究
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-03-18 DOI: 10.1155/2024/1266139
Shu Zhou, Qi Sun, Ning Gao, Zekai Hu, Junjun Jia, Jiangwei Song, Guocong Xu, Aiqiang Dong, Weiliang Xia, Jiafeng Wu
Background. While observation studies have shown a positive correlation between inflammatory bowel disease (IBD) and the risk of nonmalignant digestive system diseases, a definitive causal relationship has not yet been clearly established. Methods. Mendelian randomization (MR) was employed to investigate the potential causal association between genetic susceptibility to IBD and nonmalignant gastrointestinal diseases. Genetic variants were extracted as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis, which included 12,194 cases of Crohn’s disease (CD) and 28,072 control cases of European ancestry. The GWAS for ulcerative colitis (UC) included 12,366 UC and 33,609 control cases of European ancestry. All IVs reached genome-wide significance (GWAS value <5 × 10−8). Summary-level data for acute pancreatitis (AP), irritable bowel syndrome (IBS), gastroesophageal reflux disease, cholelithiasis, and CeD (celiac disease) were obtained from the GWAS meta-analysis and the FinnGen dataset. Summary-level data on relevant inflammatory factors were provided by the International Genetic Consortium. Univariate MR analysis was conducted using inverse variance weighting as the primary method for estimating causal effects. Multivariate MR analyses were also performed to detect possible mediators. Results. Genetic susceptibility to UC was associated with an increased risk of AP (OR = 1.08; 95% CI = 1.03–1.13; ) and IBS odds ratio (OR] = 1.07; 95% confidence interval (CI] = 1.03–1.11; (
背景。尽管观察研究显示炎症性肠病(IBD)与非恶性消化系统疾病的风险呈正相关,但尚未明确确定两者之间的因果关系。研究方法采用孟德尔随机法(MR)研究 IBD 遗传易感性与非恶性消化系统疾病之间的潜在因果关系。遗传变异是从一项全基因组关联研究(GWAS)荟萃分析中提取的工具变量(IV),该荟萃分析包括 12,194 例克罗恩病(CD)病例和 28,072 例欧洲血统对照病例。溃疡性结肠炎(UC)的 GWAS 包括 12366 例 UC 病例和 33609 例欧洲血统的对照病例。所有 IV 均达到全基因组显著性(GWAS 值为 5 × 10-8)。急性胰腺炎(AP)、肠易激综合征(IBS)、胃食管反流病、胆石症和乳糜泻(CeD)的汇总数据来自 GWAS meta 分析和 FinnGen 数据集。相关炎症因素的摘要级数据由国际遗传学联合会提供。采用反方差加权法进行单变量 MR 分析,作为估计因果效应的主要方法。还进行了多变量磁共振分析,以检测可能的中介因素。结果显示UC 遗传易感性与 AP 风险增加有关(OR = 1.08;95% CI = 1.03-1.13;),与 IBS 机率比 (OR] = 1.07;95% 置信区间 (CI] = 1.03-1.11;()有关。就潜在的介导因素而言,白细胞介素 6(IL-6)对 UC 和 AP 之间的关联具有推动作用。没有明显证据表明 CD 会增加风险。同时,对 CD 的遗传易感性会增加 CeD 的风险(OR = 1.14;95% CI = 1.03-1.25;)。结论。证据表明,UC 与 AP 和 IBS 风险升高有关,IL-6 可能是 AP 的罪魁祸首。CD 与罹患 CeD 的风险增加有关。为评估 UC 患者(尤其是 IL-6 水平升高的患者)罹患胃肠道疾病的风险而实施的前瞻性监测计划可能值得关注。此外,AP 和 IBS 的存在可能预示着 UC 的存在。在对 CD 患者进行治疗管理时,预防 CeD 是一个重要的考虑因素。
{"title":"The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study","authors":"Shu Zhou, Qi Sun, Ning Gao, Zekai Hu, Junjun Jia, Jiangwei Song, Guocong Xu, Aiqiang Dong, Weiliang Xia, Jiafeng Wu","doi":"10.1155/2024/1266139","DOIUrl":"https://doi.org/10.1155/2024/1266139","url":null,"abstract":"<i>Background</i>. While observation studies have shown a positive correlation between inflammatory bowel disease (IBD) and the risk of nonmalignant digestive system diseases, a definitive causal relationship has not yet been clearly established. <i>Methods</i>. Mendelian randomization (MR) was employed to investigate the potential causal association between genetic susceptibility to IBD and nonmalignant gastrointestinal diseases. Genetic variants were extracted as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis, which included 12,194 cases of Crohn’s disease (CD) and 28,072 control cases of European ancestry. The GWAS for ulcerative colitis (UC) included 12,366 UC and 33,609 control cases of European ancestry. All IVs reached genome-wide significance (GWAS <svg height=\"10.2124pt\" style=\"vertical-align:-3.42943pt\" version=\"1.1\" viewbox=\"-0.0498162 -6.78297 7.83752 10.2124\" width=\"7.83752pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g></svg> value &lt;5 × 10<sup>−8</sup>). Summary-level data for acute pancreatitis (AP), irritable bowel syndrome (IBS), gastroesophageal reflux disease, cholelithiasis, and CeD (celiac disease) were obtained from the GWAS meta-analysis and the FinnGen dataset. Summary-level data on relevant inflammatory factors were provided by the International Genetic Consortium. Univariate MR analysis was conducted using inverse variance weighting as the primary method for estimating causal effects. Multivariate MR analyses were also performed to detect possible mediators. <i>Results</i>. Genetic susceptibility to UC was associated with an increased risk of AP (OR = 1.08; 95% CI = 1.03–1.13; <span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.34882 18.973 11.7782\" width=\"18.973pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"><use xlink:href=\"#g113-113\"></use></g><g transform=\"matrix(.013,0,0,-0.013,11.342,0)\"></path></g></svg><span></span><span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"22.555183800000002 -8.34882 28.184 11.7782\" width=\"28.184pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.605,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,28.845,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,31.809,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.049,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.289,0)\"></path></g></svg>)</span></span> and IBS odds ratio (OR] = 1.07; 95% confidence interval (CI] = 1.03–1.11; (<span><svg height=\"11.7782pt\" style=\"vertical-align:-3.42938pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.34882 18.973 11.7782\" width=\"18.973pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"26 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140149529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma MiRNA-497与肝细胞癌预后的元分析
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-03-18 DOI: 10.1155/2024/2211179
Zhiqiang Xie, Qingzhi Hao, Rongrong Zhu, Ruiping Ma
Background. Recently, microRNA-497 (miR-497) has been reported as a prognostic marker for hepatocellular carcinoma (HCC). However, there is no systematic study summarizing these data. Herein, we elucidated the prognostic role of miR497 in HCC by using meta-analysis. Methods. We systematically searched Embase, PubMed, Web of Science, and, China National Knowledge Infrastructure for relevant studies. The two researchers conducted data extraction and quality evaluation independently. We used hazard ratios (HRs), odds ratios (ORs), and their 95% confidence interval (95% CI) to evaluate the relationship between miR-497 expression level and HCC prognosis. Results. A total of 6 studies involving 457 participants were included in this meta-analysis. There was a significant association between the lower level of miR-497 expression and the shorter overall survival (HR = 2.17, 95% CI: 1.67–2.84, ). Meanwhile, patients with low miR-497 expression were more prone to vascular infiltration (OR = 2.73, 95%: 1.79–4.17,
背景。最近有报道称,microRNA-497(miR-497)是肝细胞癌(HCC)的预后标志物。然而,目前还没有系统的研究对这些数据进行总结。在此,我们通过荟萃分析阐明了 miR497 在 HCC 中的预后作用。研究方法我们系统地检索了 Embase、PubMed、Web of Science 和中国国家知识基础设施中的相关研究。两名研究人员独立进行数据提取和质量评估。我们使用危险比(HRs)、几率比(ORs)及其 95% 置信区间(95% CI)来评估 miR-497 表达水平与 HCC 预后之间的关系。研究结果本次荟萃分析共纳入了 6 项研究,涉及 457 名参与者。miR-497表达水平越低,总生存期越短(HR = 2.17,95% CI:1.67-2.84)。同时,miR-497表达水平低的患者更容易出现血管浸润(OR = 2.73,95%:1.79-4.17,)。然而,miR-497的低表达水平与TNM(肿瘤-结节-转移)分期无明显相关性(OR = 1.47,95% CI:0.17-12.49,)。结论MiR-497可作为HCC的预后生物标志物,但还需要更多的临床研究来证实这一观点。
{"title":"A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma","authors":"Zhiqiang Xie, Qingzhi Hao, Rongrong Zhu, Ruiping Ma","doi":"10.1155/2024/2211179","DOIUrl":"https://doi.org/10.1155/2024/2211179","url":null,"abstract":"<i>Background</i>. Recently, microRNA-497 (miR-497) has been reported as a prognostic marker for hepatocellular carcinoma (HCC). However, there is no systematic study summarizing these data. Herein, we elucidated the prognostic role of miR497 in HCC by using meta-analysis. <i>Methods</i>. We systematically searched Embase, PubMed, Web of Science, and, China National Knowledge Infrastructure for relevant studies. The two researchers conducted data extraction and quality evaluation independently. We used hazard ratios (HRs), odds ratios (ORs), and their 95% confidence interval (95% CI) to evaluate the relationship between miR-497 expression level and HCC prognosis. <i>Results</i>. A total of 6 studies involving 457 participants were included in this meta-analysis. There was a significant association between the lower level of miR-497 expression and the shorter overall survival (HR = 2.17, 95% CI: 1.67–2.84, <span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.6359 19.289 9.2729\" width=\"19.289pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,11.658,0)\"></path></g></svg><span></span><span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"22.8711838 -8.6359 28.182 9.2729\" width=\"28.182pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.921,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,29.161,0)\"></path></g><g transform=\"matrix(.013,0,0,-0.013,32.125,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.365,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.605,0)\"></path></g></svg>).</span></span> Meanwhile, patients with low miR-497 expression were more prone to vascular infiltration (OR = 2.73, 95%: 1.79–4.17, <span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"-0.0498162 -8.6359 19.289 9.2729\" width=\"19.289pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,0,0)\"><use xlink:href=\"#g113-81\"></use></g><g transform=\"matrix(.013,0,0,-0.013,11.658,0)\"><use xlink:href=\"#g117-91\"></use></g></svg><span></span><span><svg height=\"9.2729pt\" style=\"vertical-align:-0.6370001pt\" version=\"1.1\" viewbox=\"22.8711838 -8.6359 28.182 9.2729\" width=\"28.182pt\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><g transform=\"matrix(.013,0,0,-0.013,22.921,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,29.161,0)\"><use xlink:href=\"#g113-47\"></use></g><g transform=\"matrix(.013,0,0,-0.013,32.125,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,38.365,0)\"><use xlink:href=\"#g113-49\"></use></g><g transform=\"matrix(.013,0,0,-0.013,44.605,0)\"><use xlink:href=\"#g113","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"21 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140149528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis C Virus Infection and Hospital-Related Outcomes: A Systematic Review 丙型肝炎病毒感染与医院相关结果:系统回顾
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-03-07 DOI: 10.1155/2024/3325609
Michelle Ng, Patrizia Maria Carrieri, Lindila Awendila, Maria Eugenia Socías, Rod Knight, Lianping Ti
Background. People living with hepatitis C infection (HCV) have a significant impact on the global healthcare system, with high rates of inpatient service use. Direct-acting antivirals (DAAs) have the potential to alleviate this burden; however, the evidence on the impact of HCV infection and hospital outcomes is undetermined. This systematic review aims to assess this research gap, including how DAAs may modify the relationship between HCV infection and hospital-related outcomes. Methods. We searched five databases up to August 2022 to identify relevant studies evaluating the impact of HCV infection on hospital-related outcomes. We created an electronic database of potentially eligible articles, removed duplicates, and then independently screened titles, abstracts, and full-text articles. Results. A total of 57 studies were included. Analysis of the included studies found an association between HCV infection and increased number of hospitalizations, length of stay, and readmissions. There was less consistent evidence of a relationship between HCV and in-hospital mortality. Only four studies examined the impact of DAAs, which showed that DAAs were associated with a reduction in hospitalizations and mortality. In the 14 studies available among people living with HIV, HCV coinfection similarly increased hospitalization, but there was less evidence for the other hospital-related outcomes. Conclusions. There is good to high-quality evidence that HCV negatively impacts hospital-related outcomes, primarily through increased hospitalizations, length of stay, and readmissions. Given the paucity of studies on the effect of DAAs on hospital outcomes, future research is needed to understand their impact on hospital-related outcomes.
背景。丙型肝炎感染者(HCV)对全球医疗保健系统产生了重大影响,其住院服务使用率很高。直接作用抗病毒药物(DAAs)有可能减轻这一负担;然而,有关 HCV 感染和住院结果影响的证据尚未确定。本系统综述旨在评估这一研究空白,包括 DAAs 如何改变 HCV 感染与医院相关结果之间的关系。方法。我们检索了截至 2022 年 8 月的五个数据库,以确定评估 HCV 感染对医院相关预后影响的相关研究。我们创建了一个潜在合格文章的电子数据库,删除了重复的文章,然后独立筛选了标题、摘要和全文。结果。共纳入 57 项研究。对纳入研究的分析发现,HCV 感染与住院次数、住院时间和再入院率的增加存在关联。关于 HCV 与院内死亡率之间关系的证据不太一致。只有四项研究考察了 DAAs 的影响,结果表明 DAAs 与住院次数和死亡率的减少有关。在针对艾滋病病毒感染者的 14 项研究中,HCV 合并感染同样会增加住院率,但其他医院相关结果的证据较少。结论。有高质量的证据表明,HCV 对医院相关结果有负面影响,主要是通过增加住院次数、住院时间和再入院率。鉴于有关 DAAs 对医院预后影响的研究较少,未来需要开展研究以了解其对医院相关预后的影响。
{"title":"Hepatitis C Virus Infection and Hospital-Related Outcomes: A Systematic Review","authors":"Michelle Ng, Patrizia Maria Carrieri, Lindila Awendila, Maria Eugenia Socías, Rod Knight, Lianping Ti","doi":"10.1155/2024/3325609","DOIUrl":"https://doi.org/10.1155/2024/3325609","url":null,"abstract":"<i>Background</i>. People living with hepatitis C infection (HCV) have a significant impact on the global healthcare system, with high rates of inpatient service use. Direct-acting antivirals (DAAs) have the potential to alleviate this burden; however, the evidence on the impact of HCV infection and hospital outcomes is undetermined. This systematic review aims to assess this research gap, including how DAAs may modify the relationship between HCV infection and hospital-related outcomes. <i>Methods</i>. We searched five databases up to August 2022 to identify relevant studies evaluating the impact of HCV infection on hospital-related outcomes. We created an electronic database of potentially eligible articles, removed duplicates, and then independently screened titles, abstracts, and full-text articles. <i>Results</i>. A total of 57 studies were included. Analysis of the included studies found an association between HCV infection and increased number of hospitalizations, length of stay, and readmissions. There was less consistent evidence of a relationship between HCV and in-hospital mortality. Only four studies examined the impact of DAAs, which showed that DAAs were associated with a reduction in hospitalizations and mortality. In the 14 studies available among people living with HIV, HCV coinfection similarly increased hospitalization, but there was less evidence for the other hospital-related outcomes. <i>Conclusions</i>. There is good to high-quality evidence that HCV negatively impacts hospital-related outcomes, primarily through increased hospitalizations, length of stay, and readmissions. Given the paucity of studies on the effect of DAAs on hospital outcomes, future research is needed to understand their impact on hospital-related outcomes.","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"24 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140055948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study 移民中丙型肝炎的医疗成本和死亡率:基于人口的匹配队列研究
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-02-24 DOI: 10.1155/2024/5573068
Aysegul Erman, Yeva Sahakyan, Karl Everett, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, William W. L. Wong, Hong Lu, Beate Sander
Background. Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada. Methods. We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival. Results. We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6–3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: −25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448. Conclusions. Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.
背景。有关移民中慢性丙型肝炎 (CHC) 经济负担的数据非常有限。我们的目标是估算加拿大安大略省移民中可归因于 CHC 的死亡率和医疗成本。方法。我们利用关联的健康管理数据,对 2003 年 5 月 31 日至 2018 年 12 月 31 日期间确诊为 CHC 的移民进行了基于人群的匹配队列研究。患有 CHC 的移民(暴露)与未患有 CHC 的移民 1 :采用硬性(指数日期、性别和年龄)和倾向分数匹配相结合的方法,将患有 CHC 的移民与未患有 CHC 的移民(未暴露)进行 1 : 1 匹配。从医疗支付方角度收集的净成本(2020 年加元)采用阶段性护理方法计算,并用于估算根据存活率调整后的长期成本。结果。我们将 5,575 名暴露者与未暴露者进行了匹配,实现了均衡匹配。平均年龄为 47 岁,52% 为男性。平均而言,10.5% 的暴露者和 3.5% 的未暴露者在指数发布后 15 年死亡(相对风险 = 2.9;95% 置信区间 (CI):2.6-3.5)。每人 30 天的净成本为:诊断前 88 美元(95% CI:55 至 122),初期 324 美元(95% CI:291 至 356),后期 1 016 美元(95% CI:900 至 1 132),末期 975 美元(95% CI:-25 至 1 974)。根据 15 年存活率调整后的平均净医疗成本为 90,448 美元。结论。与未接触过 CHC 的移民相比,感染 CHC 的移民死亡率更高,医疗成本也更高。这些发现将有助于规划在该省主要风险群体中消除丙型肝炎病毒的工作。
{"title":"Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study","authors":"Aysegul Erman, Yeva Sahakyan, Karl Everett, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, William W. L. Wong, Hong Lu, Beate Sander","doi":"10.1155/2024/5573068","DOIUrl":"https://doi.org/10.1155/2024/5573068","url":null,"abstract":"<i>Background</i>. Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada. <i>Methods</i>. We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival. <i>Results</i>. We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6–3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: −25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448. <i>Conclusions</i>. Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"6 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139954431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Esophageal Eosinophilia, Eosinophilic Esophagitis, and Lymphocytic Gastritis in Children with Celiac Disease: A Saudi Tertiary Center Experience 乳糜泻患儿食管嗜酸性粒细胞增多症、嗜酸性粒细胞性食管炎和淋巴细胞性胃炎的患病率:沙特三级医疗中心的经验
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2024-01-09 DOI: 10.1155/2024/5541687
Meshari A. Alaifan, Ammar Khayat, Rana Y. Bokhary, Abdulhameed Ibrahim, Yagoub Bin-Taleb, Bakr H. Alhussaini, Omar I. Saadah
Background. Celiac disease (CD) is an immune-mediated enteropathy that has been associated with other immune-related gastrointestinal disorders, such as eosinophilic esophagitis (EoE) and lymphocytic gastritis (LG). To our knowledge, this is the first study in Saudi Arabia that has described such an association. Aim. To evaluate the prevalence of EoE and LG in children and adolescents with CD. Methods. This was a retrospective cross-sectional study of all pediatric patients (aged 0–18 years) with CD following up at King Abdulaziz University Hospital, between January, 2014, and December, 2021. The study examined clinical, demographic, endoscopic, and histopathological data. Results. Seventy-five patients with CD were included in the analysis. The median age was 12 years (range, 2–18 years). Male constituted 54.7% of the overall cohort (n = 41). The most common clinical symptoms were short stature (54.7%), weight loss (34.7%), abdominal pain (33.3%), abdominal distension (29.3%), anorexia (29.3%), diarrhea (24%), and vomiting (21.3%). The esophageal biopsy results reported were basal cell hyperplasia in 24 patients (32.9%), esophageal eosinophilia in 23 patients (31.5%), and EoE in 3 patients (4.1%). The gastric biopsy results were normal in 40 patients (53.3%). The most common abnormality was chronic inactive gastritis with no Helicobacter pylori (HP) infection (16%). LG was found in 3 patients (4%). Conclusions. The prevalence of EoE in this cohort of patients with CD was lower than the prevalence recorded in a number of other studies. Further studies are needed to determine the effects of a gluten-free diet (GFD) on EOE and LG.
背景。乳糜泻(CD)是一种免疫介导的肠病,与其他免疫相关的胃肠道疾病,如嗜酸性粒细胞食管炎(EoE)和淋巴细胞性胃炎(LG)有关联。据我们所知,这是沙特阿拉伯第一项描述这种关联的研究。研究目的评估 CD 儿童和青少年中 EoE 和 LG 的发病率。方法。这是一项回顾性横断面研究,研究对象是 2014 年 1 月至 2021 年 12 月期间在阿卜杜勒阿齐兹国王大学医院就诊的所有 CD 儿童患者(0-18 岁)。研究考察了临床、人口统计学、内窥镜和组织病理学数据。研究结果75名 CD 患者纳入分析。中位年龄为 12 岁(2-18 岁)。男性占总人数的 54.7%(n = 41)。最常见的临床症状是身材矮小(54.7%)、体重减轻(34.7%)、腹痛(33.3%)、腹胀(29.3%)、厌食(29.3%)、腹泻(24%)和呕吐(21.3%)。食管活检结果显示,24 名患者(32.9%)出现基底细胞增生,23 名患者(31.5%)出现食管嗜酸性粒细胞增多,3 名患者(4.1%)出现 EoE。40名患者(53.3%)的胃活检结果正常。最常见的异常是没有幽门螺旋杆菌(HP)感染的慢性非活动性胃炎(16%)。有 3 名患者(4%)发现了 LG。结论。本组 CD 患者的胃食管反流患病率低于其他一些研究记录的患病率。需要进一步研究确定无麸质饮食(GFD)对肠易激综合征和 LG 的影响。
{"title":"Prevalence of Esophageal Eosinophilia, Eosinophilic Esophagitis, and Lymphocytic Gastritis in Children with Celiac Disease: A Saudi Tertiary Center Experience","authors":"Meshari A. Alaifan, Ammar Khayat, Rana Y. Bokhary, Abdulhameed Ibrahim, Yagoub Bin-Taleb, Bakr H. Alhussaini, Omar I. Saadah","doi":"10.1155/2024/5541687","DOIUrl":"https://doi.org/10.1155/2024/5541687","url":null,"abstract":"<i>Background</i>. Celiac disease (CD) is an immune-mediated enteropathy that has been associated with other immune-related gastrointestinal disorders, such as eosinophilic esophagitis (EoE) and lymphocytic gastritis (LG). To our knowledge, this is the first study in Saudi Arabia that has described such an association. <i>Aim</i>. To evaluate the prevalence of EoE and LG in children and adolescents with CD. <i>Methods</i>. This was a retrospective cross-sectional study of all pediatric patients (aged 0–18 years) with CD following up at King Abdulaziz University Hospital, between January, 2014, and December, 2021. The study examined clinical, demographic, endoscopic, and histopathological data. <i>Results</i>. Seventy-five patients with CD were included in the analysis. The median age was 12 years (range, 2–18 years). Male constituted 54.7% of the overall cohort (<i>n</i> = 41). The most common clinical symptoms were short stature (54.7%), weight loss (34.7%), abdominal pain (33.3%), abdominal distension (29.3%), anorexia (29.3%), diarrhea (24%), and vomiting (21.3%). The esophageal biopsy results reported were basal cell hyperplasia in 24 patients (32.9%), esophageal eosinophilia in 23 patients (31.5%), and EoE in 3 patients (4.1%). The gastric biopsy results were normal in 40 patients (53.3%). The most common abnormality was chronic inactive gastritis with no <i>Helicobacter pylori</i> (HP) infection (16%). LG was found in 3 patients (4%). <i>Conclusions</i>. The prevalence of EoE in this cohort of patients with CD was lower than the prevalence recorded in a number of other studies. Further studies are needed to determine the effects of a gluten-free diet (GFD) on EOE and LG.","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"26 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139415617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ghrelin/GHSR Axis Induced M2 Macrophage and Alleviated Intestinal Barrier Dysfunction in a Sepsis Rat Model by Inactivating E2F1/NF-κB Signaling 胃泌素/GHSR轴通过激活E2F1/NF-κB信号诱导M2巨噬细胞并缓解败血症大鼠模型的肠屏障功能障碍
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2023-12-29 DOI: 10.1155/2023/1629777
Lei Zhu, Zhimin Dou, Wei Wu, Qiliang Hou, Sen Wang, Ziqian Yuan, Bin Li, Jian Liu
Sepsis is an inflammatory reaction disorder state that is induced by infection. The activation and regulation of the immune system play an essential role in the development of sepsis. Our previous studies have shown that ghrelin ameliorates intestinal dysfunction in sepsis. Very little is known about the mechanism of ghrelin and its receptor (GHSR) on the intestinal barrier and the immune function of macrophage regulation. Our research is to investigate the regulatory effect and molecular mechanism of the ghrelin/GHSR axis on intestinal dysfunction and macrophage polarization in septic rats. A rat model of sepsis was established by cecal ligation and puncture (CLP) operation. Then, the sepsis rats were treated with a ghrelin receptor agonist (TZP-101) or ghrelin inhibitor (obestatin). The results suggested that TZP-101 further enhanced ghrelin and GHSR expressions in the colon and spleen of septic rats and obestatin showed the opposite results. Ghrelin/GHSR axis ameliorated colonic structural destruction and intestinal epithelial tight junction injury in septic rats. In addition, the ghrelin/GHSR axis promoted M2-type polarization of macrophages, which was characterized by the decreases of IL-1β, IL-6, and TNF-α, as well as the increase of IL-10. Mechanistically, the ghrelin/GHSR axis promoted E2F2 expression and suppressed the activation of the NF-κB signaling pathway in septic rats. Collectively, targeting ghrelin/GHSR during sepsis may represent a novel therapeutic approach for the treatment of intestinal barrier injury.
败血症是一种由感染诱发的炎症反应紊乱状态。免疫系统的激活和调节在败血症的发生发展中起着至关重要的作用。我们之前的研究表明,胃泌素能改善败血症患者的肠道功能障碍。关于胃泌素及其受体(GHSR)对肠道屏障和巨噬细胞免疫功能的调节机制,目前所知甚少。我们的研究旨在探讨胃泌素/GHSR轴对脓毒症大鼠肠道功能障碍和巨噬细胞极化的调节作用及其分子机制。通过盲肠结扎术(CLP)建立了败血症大鼠模型。然后,用胃泌素受体激动剂(TZP-101)或胃泌素抑制剂(obestatin)治疗败血症大鼠。结果表明,TZP-101能进一步增强败血症大鼠结肠和脾脏中胃泌素和GHSR的表达,而obestatin则显示出相反的结果。Ghrelin/GHSR 轴可改善败血症大鼠结肠结构破坏和肠上皮紧密连接损伤。此外,胃泌素/GHSR 轴促进了巨噬细胞的 M2 型极化,其特征是 IL-1β、IL-6 和 TNF-α 的下降以及 IL-10 的增加。从机理上讲,胃泌素/GHSR 轴促进了 E2F2 的表达,并抑制了败血症大鼠 NF-κB 信号通路的激活。总而言之,在脓毒症期间靶向胃泌素/GHSR可能是治疗肠屏障损伤的一种新的治疗方法。
{"title":"Ghrelin/GHSR Axis Induced M2 Macrophage and Alleviated Intestinal Barrier Dysfunction in a Sepsis Rat Model by Inactivating E2F1/NF-κB Signaling","authors":"Lei Zhu, Zhimin Dou, Wei Wu, Qiliang Hou, Sen Wang, Ziqian Yuan, Bin Li, Jian Liu","doi":"10.1155/2023/1629777","DOIUrl":"https://doi.org/10.1155/2023/1629777","url":null,"abstract":"Sepsis is an inflammatory reaction disorder state that is induced by infection. The activation and regulation of the immune system play an essential role in the development of sepsis. Our previous studies have shown that ghrelin ameliorates intestinal dysfunction in sepsis. Very little is known about the mechanism of ghrelin and its receptor (GHSR) on the intestinal barrier and the immune function of macrophage regulation. Our research is to investigate the regulatory effect and molecular mechanism of the ghrelin/GHSR axis on intestinal dysfunction and macrophage polarization in septic rats. A rat model of sepsis was established by cecal ligation and puncture (CLP) operation. Then, the sepsis rats were treated with a ghrelin receptor agonist (TZP-101) or ghrelin inhibitor (obestatin). The results suggested that TZP-101 further enhanced ghrelin and GHSR expressions in the colon and spleen of septic rats and obestatin showed the opposite results. Ghrelin/GHSR axis ameliorated colonic structural destruction and intestinal epithelial tight junction injury in septic rats. In addition, the ghrelin/GHSR axis promoted M2-type polarization of macrophages, which was characterized by the decreases of IL-1<i>β</i>, IL-6, and TNF-<i>α</i>, as well as the increase of IL-10. Mechanistically, the ghrelin/GHSR axis promoted E2F2 expression and suppressed the activation of the NF-<i>κ</i>B signaling pathway in septic rats. Collectively, targeting ghrelin/GHSR during sepsis may represent a novel therapeutic approach for the treatment of intestinal barrier injury.","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"26 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139063148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Hepatitis B and Hepatitis C Viral Infections and Their Associated Factors among Diabetic Patients Visiting Debre Tabor Referral Hospital, Northwest Ethiopia, 2021: A Cross-Sectional Study. 2021年埃塞俄比亚西北部Debre Tabor转诊医院糖尿病患者乙型和丙型肝炎病毒感染患病率及其相关因素:一项横断面研究
IF 2.7 4区 医学 Q2 Medicine Pub Date : 2023-11-17 eCollection Date: 2023-01-01 DOI: 10.1155/2023/5077706
Debaka Belete, Dessie Kassaw, Tesfaye Andualem

Background: Viral hepatitis is a global public health problem that affects millions of people each year, causing disability and death. Hepatitis B and C viruses are the most common causes of viral hepatitis and are associated with chronic liver disease, cirrhosis, and hepatocellular carcinoma. The primary site of infection for these viruses is the liver, the primary site of hormone and glucose metabolism closely linked to diabetes mellitus (DM), which is associated with increased morbidity and mortality worldwide. As a result, assessing the coexistence of viral hepatitis and DM could be important in disease management, prevention, and control measures in DM patients.

Objective: The aim of our study is to assess the prevalence and associated factors of HBV and HCV among diabetes patients attending Debre Tabor Referral Hospital.

Methods: An institutional-based, cross-sectional study was conducted from December 1, 2021, to February 30, 2021. A systematic sampling technique was used for selecting study participants. Serum samples were screened with a rapid test kit for hepatitis B (HBV) and hepatitis C (HCV) infections. A pretested structured questionnaire was constructed to collect the data, which were later analyzed using SPSS version 23. Inferential statistics were used to evaluate the associated risk factors for the outcome variable. A p value of <0.05 was considered statistically significant.

Result: A total of 152 diabetes patients were included in this study, with 78 (51.3%) males and 74 (48.7%) females, with a mean age of 39.24 ± 17.90 years. The prevalence of HBV and HCV was 6 (3.9%) and 2 (1.3%), respectively. Most of potential risk factors such as, histories of surgical procedures, tooth extraction, hepatitis infection in the family, blood transfusion, alcohol consumption, body tattooing, and multiple sexual partners were not statistically significant for HBV and HCV infections.

Conclusion: In this study, no association was obtained between sociodemographic, clinical, and behavioural factors and the prevalence of hepatitis B and C viruses. Furthermore, there is no significant association detected between HBV or potential HCV infection and DM. Despite these results, continuing professional training programs on HBV and HCV infection, including increased vaccination coverage rates for HBV, are required.

背景:病毒性肝炎是一个全球性的公共卫生问题,每年影响数百万人,造成残疾和死亡。乙型和丙型肝炎病毒是病毒性肝炎最常见的病因,并与慢性肝病、肝硬化和肝细胞癌有关。这些病毒的主要感染部位是肝脏,这是与糖尿病(DM)密切相关的激素和葡萄糖代谢的主要部位,而糖尿病在世界范围内与发病率和死亡率增加有关。因此,评估病毒性肝炎和糖尿病的共存对糖尿病患者的疾病管理、预防和控制措施具有重要意义。目的:本研究的目的是评估在Debre Tabor转诊医院就诊的糖尿病患者中HBV和HCV的患病率及其相关因素。方法:从2021年12月1日至2021年2月30日进行了一项基于机构的横断面研究。采用系统抽样技术选择研究参与者。用快速检测试剂盒对血清样本进行乙型肝炎(HBV)和丙型肝炎(HCV)感染筛查。采用预测的结构化问卷进行数据收集,使用SPSS 23对数据进行分析。采用推理统计方法评价结果变量的相关危险因素。结果:共纳入152例糖尿病患者,其中男性78例(51.3%),女性74例(48.7%),平均年龄39.24±17.90岁。HBV和HCV的患病率分别为6(3.9%)和2(1.3%)。大多数潜在的危险因素,如外科手术史、拔牙史、家庭肝炎感染史、输血史、饮酒史、身体纹身史和多个性伴侣史,对HBV和HCV感染没有统计学意义。结论:在这项研究中,没有发现社会人口学、临床和行为因素与乙型和丙型肝炎病毒流行之间的关联。此外,没有检测到HBV或潜在HCV感染与DM之间的显著关联。尽管有这些结果,需要继续进行HBV和HCV感染的专业培训计划,包括增加HBV疫苗接种覆盖率。
{"title":"Prevalence of Hepatitis B and Hepatitis C Viral Infections and Their Associated Factors among Diabetic Patients Visiting Debre Tabor Referral Hospital, Northwest Ethiopia, 2021: A Cross-Sectional Study.","authors":"Debaka Belete, Dessie Kassaw, Tesfaye Andualem","doi":"10.1155/2023/5077706","DOIUrl":"10.1155/2023/5077706","url":null,"abstract":"<p><strong>Background: </strong>Viral hepatitis is a global public health problem that affects millions of people each year, causing disability and death. Hepatitis B and C viruses are the most common causes of viral hepatitis and are associated with chronic liver disease, cirrhosis, and hepatocellular carcinoma. The primary site of infection for these viruses is the liver, the primary site of hormone and glucose metabolism closely linked to diabetes mellitus (DM), which is associated with increased morbidity and mortality worldwide. As a result, assessing the coexistence of viral hepatitis and DM could be important in disease management, prevention, and control measures in DM patients.</p><p><strong>Objective: </strong>The aim of our study is to assess the prevalence and associated factors of HBV and HCV among diabetes patients attending Debre Tabor Referral Hospital.</p><p><strong>Methods: </strong>An institutional-based, cross-sectional study was conducted from December 1, 2021, to February 30, 2021. A systematic sampling technique was used for selecting study participants. Serum samples were screened with a rapid test kit for hepatitis B (HBV) and hepatitis C (HCV) infections. A pretested structured questionnaire was constructed to collect the data, which were later analyzed using SPSS version 23. Inferential statistics were used to evaluate the associated risk factors for the outcome variable. A <i>p</i> value of <0.05 was considered statistically significant.</p><p><strong>Result: </strong>A total of 152 diabetes patients were included in this study, with 78 (51.3%) males and 74 (48.7%) females, with a mean age of 39.24 ± 17.90 years. The prevalence of HBV and HCV was 6 (3.9%) and 2 (1.3%), respectively. Most of potential risk factors such as, histories of surgical procedures, tooth extraction, hepatitis infection in the family, blood transfusion, alcohol consumption, body tattooing, and multiple sexual partners were not statistically significant for HBV and HCV infections.</p><p><strong>Conclusion: </strong>In this study, no association was obtained between sociodemographic, clinical, and behavioural factors and the prevalence of hepatitis B and C viruses. Furthermore, there is no significant association detected between HBV or potential HCV infection and DM. Despite these results, continuing professional training programs on HBV and HCV infection, including increased vaccination coverage rates for HBV, are required.</p>","PeriodicalId":48755,"journal":{"name":"Canadian Journal of Gastroenterology and Hepatology","volume":"2023 ","pages":"5077706"},"PeriodicalIF":2.7,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673667/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Canadian Journal of Gastroenterology and Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1